TLR3 and neoplasm: Leveraging innate signaling, the same backbone combined with the TLR-3 agonist poly(I:C) re-activated NF-κB in tumor cells and tumor-associated macrophages; co-treatment amplified virus-mediated cytotoxicity and promoted M1 polarization beyond that seen with either agent alone [47].